Status:
COMPLETED
Folfiri as Third Line of Treatment
Lead Sponsor:
IRCCS Cancer Referral Center of Basilicata
Conditions:
Gastric Cancer
Ramucirumab
Eligibility:
All Genders
18+ years
Brief Summary
The aim of this study is to investigate the activity of Folfiri as Third line of treatment in mGC progressed after ramuciramb-based second line.
Eligibility Criteria
Inclusion
- Patients with histologically confirmed, ramucirumab pretreated metastatic gastric cancer who received
- Eastern Cooperative Oncology Group performance status ≤2 (ECOG PS)
- aged \> 18 years
- neutrophil count ≥1500/μl
- platelet count ≥100 000/μl),
- renal (serum creatinine ≤1.5 mg/dl)
- liver (serum bilirubin ≤2 mg/dL) functions
- normal cardiac function,
- absence of second primary tumor other than non-melanoma skin cancer
- no concurrent uncontrolled medical illness.
Exclusion
- Eastern Cooperative Oncology Group performance status \>2 (ECOG PS)
- No prior treatment with ramucirumab
- operable metastatic disease were excluded from the study
- severe cardiac dysfunction, congestive heart failure or a recent myocardial infarction
- uncontrolled sites of infection.
Key Trial Info
Start Date :
March 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 23 2018
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT03486379
Start Date
March 1 2016
End Date
March 23 2018
Last Update
April 3 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.